Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology

Key Terms

capillary whole blood sampling medical

Capillary whole blood sampling is the collection of a small drop of blood from tiny vessels near the skin surface — typically from a fingertip, heel or earlobe — that contains both blood cells and plasma. For investors, it matters because this simple, quick method enables point-of-care and at-home diagnostic tests that can lower costs, speed results and expand market access, but also brings trade-offs in accuracy, device design and regulatory approval.

micro-needle medical

A micro-needle is a very small, needle-like structure—often a patch with tiny projections—that pierces only the outer skin layer to deliver drugs or vaccines or to sample fluids without causing significant pain or bleeding. Investors watch micro-needles because they can make treatments easier, safer and cheaper to administer, potentially opening new markets and improving uptake much like a smartphone accessory that makes a useful device far more convenient and widely used.

microneedles medical

Microneedles are arrays of microscopic, pain-free needles built into a patch or device that pierce only the outer skin layer to deliver drugs, vaccines, or samples without a traditional injection — imagine a tiny stamp of fine pins that lets medicine pass through the skin. Investors care because this approach can lower treatment costs, improve patient adherence, simplify distribution and manufacturing, and open new markets for drugs that are hard to deliver by pill or syringe.

venipuncture medical

Venipuncture is the medical procedure of inserting a needle into a vein to draw blood or deliver fluids and medications, similar to tapping a garden hose to collect a sample or add water. For investors, it matters because reliable, safe venipuncture is essential for accurate lab tests, clinical trial sampling, and routine patient care—issues that affect trial timelines, diagnostic accuracy, operational costs, and regulatory or reputational risk for healthcare companies.

regulatory approvals regulatory

Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

patents technical

Patents are government-granted rights that give an inventor exclusive control to make, use, sell or license a specific invention for a limited time, like a temporary lock on a new product or process. For investors, patents matter because they can create a protected revenue stream, raise barriers for competitors, support higher valuations, and also carry risks from expiration or legal challenges.

Acquisition Combines Hims & Hers’ Leading Wellness Platform with YourBio’s Patented, Virtually Painless Micro-Needle Technology to Redefine the Future of Blood Sampling

SAN FRANCISCO & BOSTON--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio’s advanced blood sampling devices, the acquisition will help accelerate efforts to redefine and modernize the overall blood collection experience, making pain-free blood sampling the new standard.

YourBio Health develops technologies designed to simplify the process and expand when, where, and how blood samples can be collected—including beyond traditional clinic settings. Its TAP® device, built on HALO™ technology, uses bladeless microneedles thinner than an eyelash to produce high-quality capillary blood samples in seconds, without the pain or complexity of traditional methods, like fingerstick or venipuncture. Developed over years of extensive engineering, the TAP device and underlying HALO system are protected by a robust portfolio of patents covering state-of-the-art microtechnology design, sample handling, and device integration.

“The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human,” said Andrew Dudum, founder and CEO of Hims & Hers. “YourBio’s patented TAP and HALO technologies represent major advancements in user experience and design, and we’re excited to bring them into the Hims & Hers ecosystem.”

“YourBio’s HALO and TAP technologies are ushering in some of the most significant scientific advancements in the blood collection space in decades,” said Dr. Michael Mina, Chief Scientific Officer at YourBio Health. “By using micro-needles thinner than an eyelash, these systems produce high-quality blood samples with essentially no discomfort. This technology has the potential to change how people engage with routine blood collection – replacing long waits and painful needles with a far more convenient, user-friendly experience.”

“For decades, blood sampling has remained largely unchanged—forcing patients and healthcare providers through an inefficient process that causes pain and discomfort, heightens anxieties, and often takes more blood than is necessary,” said Paul Owen, CEO of YourBio Health. “By rethinking every aspect of the experience—from comfort and design to accessibility—we’re reimagining what the modern blood collection process can and should look like.”

With this acquisition, Hims & Hers will bring into its portfolio what it believes to be the most advanced, pain-free blood sampling technology to date, fueling its in-house innovation engine and redefining what’s possible in user-centric blood sampling. Dr. Michael Mina and Paul Owen will also join the Hims & Hers team, supporting the company’s efforts to drive the customer experience forward.

The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions. Consideration is comprised entirely of cash funded from Hims & Hers’ balance sheet.

For more information, please visit www.hims.com and www.yourbiohealth.com

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

About YourBio Health, Inc.

YourBio Health is a Flagship Pioneering portfolio company that invented ‘Touch-Activated Phlebotomy’ (TAP) for virtually painless whole capillary blood collection using devices incorporating patented technology. This technology eliminates barriers to blood collection by allowing a capillary blood sample to be collected from any physical location without the pain of a fingerstick or the need for traditional phlebotomy. Backed by the latest sciences, data management technology, and certified central laboratories, YourBio Health is seeking to revolutionize and humanize the blood sampling process serving clinical trials, and diagnostic and wellness applications.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ proposed acquisition of YourBio Health, the expected timing and anticipated effects of the transaction, the development and potential of blood sampling technologies, and assumptions relating to the foregoing. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties as to the timing of the proposed transaction; the failure to satisfy any of the closing conditions to the proposed transaction; delays in consummating the proposed transaction or the risk that the transaction may not close at all; unexpected liabilities, costs, charges or expenses in connection with the proposed transaction; the effects of the proposed transaction (or the announcement thereof) on the parties’ relationships with employees, customers, investors, other business partners or governmental entities; delays or challenges in developing technologies; risks related to our ability to obtain or maintain any applicable regulatory approvals; risks related to our ability to protect our intellectual property; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; development of similar technologies by competitors; challenges in product design, manufacturing or supply chain; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of the date hereof. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203779510/en/

Press Contact

Susan Cadrecha

press@forhims.com

Source: Hims & Hers